Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2479) 2479
Publication (168) 168
Newsletter (54) 54
Book Review (53) 53
Book Chapter (12) 12
Magazine Article (11) 11
Newspaper Article (7) 7
Conference Proceeding (6) 6
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1920) 1920
itraconazole (1740) 1740
male (1127) 1127
antifungal agents - therapeutic use (1042) 1042
female (1007) 1007
index medicus (824) 824
adult (801) 801
middle aged (750) 750
itraconazole - therapeutic use (697) 697
antifungal agents - adverse effects (577) 577
antifungal agents - administration & dosage (569) 569
pharmacology & pharmacy (549) 549
fluconazole (486) 486
aged (463) 463
treatment outcome (427) 427
itraconazole - administration & dosage (396) 396
itraconazole - adverse effects (391) 391
administration, oral (363) 363
drug interactions (355) 355
voriconazole (347) 347
dermatology (331) 331
infectious diseases (310) 310
antifungal agents (308) 308
adolescent (307) 307
mycoses (304) 304
pharmacokinetics (284) 284
animals (276) 276
amphotericin-b (260) 260
therapy (255) 255
terbinafine (250) 250
microbiology (233) 233
antifungal agents - pharmacology (210) 210
mycoses - drug therapy (208) 208
child (205) 205
aspergillosis - drug therapy (204) 204
onychomycosis - drug therapy (203) 203
drug therapy (202) 202
aspergillosis (198) 198
amphotericin b - therapeutic use (196) 196
ketoconazole (195) 195
antifungal agents - pharmacokinetics (194) 194
care and treatment (192) 192
immunology (192) 192
double-blind (184) 184
transplantation (184) 184
onychomycosis (183) 183
fluconazole - therapeutic use (182) 182
health aspects (181) 181
posaconazole (174) 174
drug therapy, combination (171) 171
medicine & public health (162) 162
mycology (161) 161
mycoses - prevention & control (158) 158
triazoles - therapeutic use (157) 157
diagnosis (154) 154
fungal-infections (154) 154
amphotericin b (150) 150
risk factors (150) 150
analysis (149) 149
drug administration schedule (146) 146
infection (146) 146
young adult (146) 146
itraconazole - pharmacology (145) 145
medicine, general & internal (141) 141
research (141) 141
fungal infections (140) 140
infections (139) 139
oncology (138) 138
ketoconazole - therapeutic use (135) 135
dose-response relationship, drug (128) 128
efficacy (127) 127
safety (127) 127
veterinary sciences (127) 127
retrospective studies (126) 126
immunocompromised host (122) 122
triazoles - adverse effects (120) 120
prophylaxis (119) 119
invasive aspergillosis (114) 114
dosage and administration (113) 113
fungi (112) 112
in-vitro (112) 112
dermatology & venereal diseases (111) 111
triazoles - administration & dosage (111) 111
double-blind method (110) 110
internal medicine (110) 110
pharmacology/toxicology (110) 110
drugs (109) 109
itraconazole - pharmacokinetics (109) 109
hematology (108) 108
invasive fungal-infections (108) 108
prospective studies (108) 108
cancer (106) 106
microbial sensitivity tests (106) 106
naphthalenes - therapeutic use (105) 105
epidemiology (104) 104
ketoconazole - analogs & derivatives (102) 102
liposomal amphotericin-b (101) 101
area under curve (100) 100
child, preschool (99) 99
metabolism (98) 98
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2414) 2414
Japanese (30) 30
Spanish (28) 28
French (27) 27
German (19) 19
Chinese (11) 11
Dutch (11) 11
Korean (5) 5
Russian (4) 4
Finnish (3) 3
Italian (3) 3
Polish (2) 2
Bulgarian (1) 1
Czech (1) 1
Danish (1) 1
Hungarian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents
by Benitez, Lydia L and Carver, Peggy L
Drugs, ISSN 0012-6667, 06/2019, Volume 79, Issue 8, pp. 833 - 853
Azole antifungals are first-line options in the prophylaxis and treatment of invasive fungal infections. They are often used for prolonged (weeks to months)... 
Fungicides | Transplants & implants | Fluorine | Liver | Prophylaxis | Systematic review | Fungal infections | Cancer therapies | Hematopoietic stem cells | Skin cancer | Pain | Heterocyclic compounds | Voriconazole | Hypokalemia | Hepatotoxicity | Drug dosages | Itraconazole | Gynecomastia | Squamous cell carcinoma | Hyponatremia | Baldness | Invasiveness | Antifungal agents | Pancreatitis | Fluorides | Metabolism | Hemopoiesis | Azoles | Periostitis | Alopecia | Stem cells | Posaconazole
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Cardiovascular adverse effects during itraconazole therapy
by Fung, S.-L and Chau, C.-H and Yew, W.-W
European Respiratory Journal, ISSN 0903-1936, 07/2008, Volume 32, Issue 1, pp. 240 - 240
RESPIRATORY SYSTEM | Antifungal Agents - adverse effects | Itraconazole - adverse effects | Humans | Hypertension - chemically induced | Middle Aged | Lung Diseases, Fungal - drug therapy | Female | Male | Aged | Heart Failure - chemically induced
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Update on rifampin, rifabutin, and rifapentine drug interactions
by Baciewicz, Anne M and Chrisman, Cary R and Finch, Christopher K and Self, Timothy H
Current Medical Research & Opinion, ISSN 0300-7995, 01/2013, Volume 29, Issue 1, pp. 1 - 12
Abstract Background: Rifampin is a potent inducer of both cytochrome P-450 oxidative enzymes and the P-glycoprotein transport system. Among numerous well... 
Rifabutin | Rifampin | Rifapentine | Drug interactions | MEDICINE, RESEARCH & EXPERIMENTAL | ENZYME-INDUCTION | PLATELET-AGGREGATION | TUBERCULOSIS | OPEN-LABEL | ATORVASTATIN | SINGLE-BLIND | MEDICINE, GENERAL & INTERNAL | PHARMACOKINETICS | PLASMA-CONCENTRATIONS | HEALTHY-VOLUNTEERS | TRANSPORTER INHIBITION | Rifampin - analogs & derivatives | Simvastatin - therapeutic use | Antifungal Agents - adverse effects | Digoxin - adverse effects | Simvastatin - adverse effects | Antibiotics, Antitubercular - adverse effects | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Antifungal Agents - therapeutic use | Rifampin - adverse effects | Verapamil - therapeutic use | Drug Interactions | Verapamil - adverse effects | Rifampin - therapeutic use | Contraceptives, Oral - adverse effects | Contraceptives, Oral - therapeutic use | Digoxin - therapeutic use | HIV Protease Inhibitors - adverse effects | Rifabutin - adverse effects | Anti-Arrhythmia Agents - therapeutic use | HIV Protease Inhibitors - therapeutic use | Anticholesteremic Agents - adverse effects | Itraconazole - therapeutic use | Anticholesteremic Agents - therapeutic use | Anti-Arrhythmia Agents - adverse effects | Itraconazole - adverse effects | Antibiotics, Antitubercular - therapeutic use | Cytochrome P-450 Enzyme System - biosynthesis | Rifabutin - therapeutic use | ATP Binding Cassette Transporter, Sub-Family B | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis
by Girois, S B and Chapuis, F and Decullier, E and Revol, B G. P
European Journal of Clinical Microbiology and Infectious Diseases, ISSN 0934-9723, 2/2006, Volume 25, Issue 2, pp. 138 - 149
Amphotericin B is the main therapeutic agent for the treatment of invasive fungal infections; however, it is associated with significant toxicities that limit... 
MARROW TRANSPLANT RECIPIENTS | INFECTIOUS DISEASES | MULTICENTER RANDOMIZED-TRIAL | LIPID COMPLEX | CLINICAL-TRIAL | ORAL ITRACONAZOLE | MICROBIOLOGY | NEUTROPENIC PATIENTS | COMPLEX INJECTION ABLC | HEMATOLOGIC MALIGNANCIES | COLLOIDAL DISPERSION | LIPOSOMAL AMPHOTERICIN-B | Antifungal Agents - adverse effects | Humans | Hypokalemia - chemically induced | Kidney Diseases - chemically induced | Mycoses - drug therapy | Chemical and Drug Induced Liver Injury | Antifungal Agents - therapeutic use | Decision-making | Complications and side effects | Amphotericin B | Analysis | Mycoses | Antiparasitic agents | Itraconazole | Fungi | Medical treatment | Fungal infections
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text The investigational drug VT-1129 is a highly potent inhibitor of Cryptococcus species CYP51 but only weakly inhibits the human enzyme
by Warrilow, Andrew G. S and Parker, Josie E and Price, Claire L and Nes, W. David and Garvey, Edward P and Hoekstra, William J and Schotzinger, Robert J and Kelly, Diane E and Kelly, Steven L
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 08/2016, Volume 60, Issue 8, pp. 4530 - 4538
Cryptococcosis is a life-threatening disease often associated with HIV infection. Three Cryptococcus species CYP51 enzymes were purified and catalyzed the 14... 
CANDIDA-ALBICANS | NEOFORMANS | STEROL 14-ALPHA-DEMETHYLASE | ESCHERICHIA-COLI | MOLECULAR TYPE | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | HUMAN LIVER-MICROSOMES | EPIDEMIOLOGIC CUTOFF VALUES | AZOLE ANTIFUNGAL AGENTS | AIDS PATIENTS | LANOSTEROL 14-ALPHA-DEMETHYLASE | Antifungal Agents - pharmacology | Cryptococcus - metabolism | Antifungal Agents - adverse effects | Fluconazole - pharmacology | Tetrazoles - pharmacology | Ergosterol - metabolism | Voriconazole - adverse effects | Voriconazole - pharmacology | Humans | Clotrimazole - pharmacology | Fluconazole - adverse effects | Lanosterol - analogs & derivatives | Enzyme Activation - drug effects | Itraconazole - pharmacology | Ketoconazole - pharmacology | Pyridines - adverse effects | Clotrimazole - adverse effects | Itraconazole - adverse effects | Lanosterol - metabolism | Pyridines - pharmacology | Sterol 14-Demethylase - metabolism | Ketoconazole - adverse effects | Tetrazoles - adverse effects | Cryptococcus - drug effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
by Cornely, Oliver A and Maertens, Johan and Winston, Drew J and Perfect, John and Ullmann, Andrew J and Walsh, Thomas J and Helfgott, David and Holowiecki, Jerzy and Stockelberg, Dick and Goh, Yeow-Tee and Petrini, Mario and Hardalo, Cathy and Suresh, Ramachandran and Angulo-Gonzalez, David
The New England Journal of Medicine, ISSN 0028-4793, 01/2007, Volume 356, Issue 4, pp. 348 - 359
In this randomized trial of patients undergoing treatment for acute myelogenous leukemia or the myelodysplastic syndrome, prophylaxis with posaconazole... 
CONTROLLED-TRIALS | MEDICINE, GENERAL & INTERNAL | ORAL FLUCONAZOLE | CANCER-PATIENTS | STEM-CELL TRANSPLANTS | ANTIFUNGAL PROPHYLAXIS | DOUBLE-BLIND | RANDOMIZED-TRIAL | INVASIVE FUNGAL-INFECTIONS | HEMATOLOGIC MALIGNANCIES | MARROW TRANSPLANTATION | Single-Blind Method | Triazoles - adverse effects | Antifungal Agents - adverse effects | Humans | Middle Aged | Fluconazole - adverse effects | Male | Opportunistic Infections - prevention & control | Leukemia, Myeloid, Acute - complications | Fluconazole - therapeutic use | Antifungal Agents - therapeutic use | Antineoplastic Agents - adverse effects | Neutropenia - mortality | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Neutropenia - chemically induced | Myelodysplastic Syndromes - drug therapy | Triazoles - therapeutic use | Mycoses - prevention & control | Kaplan-Meier Estimate | Treatment Outcome | Myelodysplastic Syndromes - complications | Neutropenia - drug therapy | Itraconazole - therapeutic use | Leukemia, Myeloid, Acute - mortality | Itraconazole - adverse effects | Adolescent | Myelodysplastic Syndromes - mortality | Aged | Mycoses - mortality | Fluconazole | Comparative analysis | Fungi | Infections | Fungal infections | Mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Oral Erythromycin and the Risk of Sudden Death from Cardiac Causes
by Ray, Wayne A and Murray, Katherine T and Meredith, Sarah and Narasimhulu, Sukumar Suguna and Hall, Kathi and Stein, C. Michael
The New England Journal of Medicine, ISSN 0028-4793, 09/2004, Volume 351, Issue 11, pp. 1089 - 1096
Erythromycin is known to prolong cardiac repolarization and has been associated with case reports of torsades de pointes. In this study, the use of oral... 
TERFENADINE | CLARITHROMYCIN | MEDICINE, GENERAL & INTERNAL | TORSADES-DE-POINTES | PHARMACOKINETICS | CISAPRIDE | PHARMACOEPIDEMIOLOGY | KETOCONAZOLE | PROLONGATION | ITRACONAZOLE | MIDAZOLAM | Multivariate Analysis | Calcium Channel Blockers - adverse effects | Cytochrome P-450 CYP3A | Humans | Middle Aged | Male | Risk | Death, Sudden, Cardiac - etiology | Anti-Bacterial Agents - therapeutic use | Nitroimidazoles - adverse effects | Drug Interactions | Oxidoreductases, N-Demethylating - antagonists & inhibitors | Verapamil - adverse effects | Adult | Female | Anti-Bacterial Agents - adverse effects | Oxidoreductases, N-Demethylating - metabolism | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Administration, Oral | Troleandomycin - adverse effects | Erythromycin - therapeutic use | Aryl Hydrocarbon Hydroxylases - metabolism | Diltiazem - adverse effects | Erythromycin - adverse effects | Confounding Factors (Epidemiology) | Amoxicillin - therapeutic use | Aged | Medical research | Sudden death | Causes of | Medicine, Experimental | Research | Erythromycin | Risk factors | Studies | Drug therapy | Medicaid
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Interventions for Old World cutaneous leishmaniasis
by Heras-Mosteiro, Julio and Monge-Maillo, Begoña and Pinart, Mariona and Lopez Pereira, Patricia and Garcia-Carrasco, Emely and Campuzano Cuadrado, Pedro and Royuela, Ana and Mendez Roman, Irene and López-Vélez, Rogelio
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 11/2017, Volume 2017, Issue 11, p. CD005067
Background Cutaneous leishmaniasis, caused by a parasitic infection, is considered one of the most serious skin diseases in many low-and middle-income... 
MEDICINE, GENERAL & INTERNAL | AMINOSIDINE PAROMOMYCIN OINTMENT | LOCAL HEAT THERAPY | RANDOMIZED CLINICAL-TRIAL | AMPHOTERICIN-B AMBISOME(R) | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | TOPICAL PAROMOMYCIN | HYPERTONIC SODIUM-CHLORIDE | VISCERAL LEISHMANIASIS | INTRALESIONAL MEGLUMINE ANTIMONIATE | Hot Temperature - therapeutic use | Paromomycin - adverse effects | Anti-Infective Agents - adverse effects | Paromomycin - therapeutic use | Humans | Laser Therapy | Anti-Infective Agents - therapeutic use | Photochemotherapy | Randomized Controlled Trials as Topic | Itraconazole - therapeutic use | Complementary Therapies | Animals | Antiprotozoal Agents - adverse effects | Itraconazole - adverse effects | Leishmaniasis, Cutaneous - therapy | Leishmania tropica | Antiprotozoal Agents - therapeutic use | Cryotherapy | Leishmania major
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses
by Thompson, George R and Rendon, Adrian and Ribeiro Dos Santos, Rodrigo and Queiroz-Telles, Flavio and Ostrosky-Zeichner, Luis and Azie, Nkechi and Maher, Rochelle and Lee, Misun and Kovanda, Laura and Engelhardt, Marc and Vazquez, Jose A and Cornely, Oliver A and Perfect, John R
Clinical Infectious Diseases, ISSN 1058-4838, 08/2016, Volume 63, Issue 3, pp. 356 - 362
Background. Invasive fungal diseases (IFD) caused by Cryptococcus and dimorphic fungi are associated with significant morbidity and mortality. Isavuconazole... 
paracoccidioidomycosis | coccidioidomycosis | blastomycosis | histoplasmosis | cryptococcosis | VORICONAZOLE | INFECTIOUS DISEASES | ENDEMIC MYCOSES | MICROBIOLOGY | ITRACONAZOLE | IMMUNOLOGY | FUNGAL-INFECTIONS | CLINICAL-PRACTICE GUIDELINES | PHARMACODYNAMIC TARGET DETERMINATION | OF-AMERICA | UPDATE | INFECTIOUS-DISEASES-SOCIETY | Triazoles - adverse effects | Antifungal Agents - adverse effects | Cryptococcosis - microbiology | Nitriles - pharmacology | Humans | Middle Aged | Mycoses - microbiology | Male | Cryptococcosis - drug therapy | Histoplasmosis - microbiology | Paracoccidioidomycosis - drug therapy | Young Adult | Pyridines - adverse effects | Blastomycosis - drug therapy | Adult | Female | Coccidioidomycosis - drug therapy | Antifungal Agents - pharmacology | Coccidioidomycosis - microbiology | Triazoles - pharmacology | Paracoccidioidomycosis - microbiology | Mycoses - drug therapy | Aged | Pyridines - pharmacology | Blastomycosis - microbiology | Histoplasmosis - drug therapy | Nitriles - adverse effects | Cryptococcal infections | Mycoses | Care and treatment | and Commentaries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers
by Gopal Krishna and Allen Moton and Lei Ma and Matthew M. Medlock and James McLeod
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 03/2009, Volume 53, Issue 3, pp. 958 - 966
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
CELL TRANSPLANT RECIPIENTS | STEADY-STATE PHARMACOKINETICS | BEVERAGE COCA-COLA | SALVAGE THERAPY | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | FOOD INTERACTION | INVASIVE FUNGAL-INFECTION | ITRACONAZOLE | TRIAZOLE ANTIFUNGAL | VERSUS-HOST-DISEASE | FLUCONAZOLE | Triazoles - administration & dosage | Triazoles - adverse effects | Antifungal Agents - adverse effects | Triazoles - blood | Area Under Curve | Humans | Middle Aged | Omeprazole - blood | Intestinal Absorption - drug effects | Male | Anti-Ulcer Agents - blood | Gastric Mucosa - metabolism | Anti-Ulcer Agents - pharmacokinetics | Dose-Response Relationship, Drug | Young Adult | Antifungal Agents - pharmacokinetics | Hydrogen-Ion Concentration - drug effects | Gastric Mucosa - drug effects | Adult | Female | Triazoles - pharmacokinetics | Suspensions | Eating | European Continental Ancestry Group - genetics | Fasting | Drug Administration Schedule | Administration, Oral | Food-Drug Interactions | Omeprazole - administration & dosage | Anti-Ulcer Agents - adverse effects | African Americans - genetics | European Continental Ancestry Group - statistics & numerical data | Omeprazole - adverse effects | Omeprazole - pharmacokinetics | Carbonated Beverages | Anti-Ulcer Agents - administration & dosage | Cross-Over Studies | African Americans - statistics & numerical data | Antifungal Agents - administration & dosage | Antifungal Agents - blood | Index Medicus | Pharmacology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights